Last reviewed · How we verify

NCT05367869: methylene

Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy

Status unknown NA Last updated 24 May 2022
What this trial tests

NA trial testing Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy in Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy in 40 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
31 May 2023
31 May 2023

Quick facts

Lead sponsorQena Oncology Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 June 2022
Primary completion31 May 2023
Estimated completion31 May 2023

Drugs / interventions tested

Conditions studied

Sponsor

Qena Oncology Center

Who can join

Adults 15 to 80, any sex, with Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Impact of Intraoperative Spraying methylene blue In thyroidectomy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qena Oncology Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing